Table 2.
Treatment Outcomes Among Osteosarcoma Patients Treated in Clinical Trial of Palliative Radiotherapy and Intra-tumoral Autologous NK Cells
| Patient | Age (years) | Total NK Cells Injected (× 106) | Toxicity | Status | Survival Time (months) | Cause of Deatha | 6-Month Metastasis-Free Survivalb |
|---|---|---|---|---|---|---|---|
| 1 | 14.8 | 30.3 | Dead | 2.4 | Metastases | No | |
| 2 | 9.1 | 25.34 | Infection at injection site | Alive | 8.1 | n/a | Yes |
| 3 | 9.1 | 547 | Alive | 11.2 | n/a | Yesc | |
| 4 | 5.8 | 254.33 | Alive | 6.0 | n/a | Yes | |
| 5 | 1.2 | 102.63 | Grade 3 fever/chills/dehydration attributed to rhIL-2 reaction; Infection at injection site requiring surgery | Dead | 8.1 | Metastases | Yes |
| 6 | 6.3 | 216.4 | Infection at injection site requiring surgery | Dead | 4.1 | Perforated ulcer | No |
| 7 | 7.5 | 234 | Dead | 2.9 | Pathologic fracture/ metastases | No | |
| 8 | 5.0 | 305 | Dead | 1.6 | Pathologic fracture | No | |
| 9 | 8.9 | 355 | Alive | 7.6 | n/a | Yes | |
| 10 | 10.2 | 132 | Dead | 5.0 | Metastases | No |
aAnimals were euthanized at owner’s request following diagnosis of index event
bFreedom from pulmonary metastasis 6 months after enrollment was the primary endpoint of the clinical trial
cPatient demonstrated resolution of suspicious pulmonary nodule post-radioimmunotherapy